Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
SAR-bisNTR1's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for SAR-bisNTR1. Showing past 6 months and next 12 months · 5 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| SAR-bisNTR1 | Clarity Pharmaceuticals | Radioligand Other | Phase 1 | 0 | ||||
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years | Guerbet | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors | Jiangsu HengRui Medicine Co., Ltd. | — | Phase 3 | — | — | — | — | — |
| 18F-DOPA II - PET Imaging Optimization | University of Alberta | — | Phase 3 | — | — | — | — | — |
| Pancreatic Cancer Diagnosis With FAPI-PET Imaging | Turku University Hospital | — | PHASE2/PHASE3 | — | — | — | — | — |
| Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types | KU Leuven | — | PHASE2/PHASE3 | — | — | — | — | — |
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | GE Healthcare | — | PHASE2/PHASE3 | — | — | — | — | — |
| NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101 | Leiden University Medical Center | — | Phase 2 | — | — | — | — | — |
| Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma | Mayo Clinic | — | Phase 2 | — | — | — | — | — |
| 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) | Institut Curie | — | Phase 2 | — | — | — | — | — |
| 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Lantheus Medical Imaging | — | PHASE1/PHASE2 | — | — | — | — | — |
| Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | Lumicell, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | George Poultsides | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | ITM Oncologics GmbH | — | PHASE1/PHASE2 | — | — | — | — | — |
| [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | Blue Earth Diagnostics | — | PHASE1/PHASE2 | — | — | — | — | — |